Kaer Biotherapeutics

Executive Summary

Kaer Biotherapeutics, founded in 2019 and headquartered in San Diego, is a private biotechnology company developing innovative aerosol delivery platforms—AeroPulsR and SUPRAER-Clinic—for rapid administration of high-dose therapeutics to treat life-threatening respiratory disorders. The company's technology targets critical care settings including NICU, PICU, ICU, emergency rooms, and surgical suites, addressing an unmet need for efficient, non-invasive drug delivery in acute respiratory conditions. By enabling precise dosing and rapid onset, Kaer's platforms aim to improve outcomes for patients with severe respiratory distress, such as those with COVID-19, ARDS, or pediatric respiratory infections. The company operates at the intersection of immunology, oncology, and antibody therapeutics, suggesting potential applications beyond respiratory diseases. While Kaer is in its early stages and lacks disclosed funding or pipeline specifics, its focused approach on a commercialized clinical device positions it for potential adoption in hospital settings. The absence of disclosed clinical data or regulatory milestones limits visibility, but the technology's relevance to pandemic preparedness and critical care innovation presents a compelling niche opportunity.

Upcoming Catalysts (preview)

• Q2 2026FDA 510(k) clearance or CE marking for SUPRAER-Clinic device60% success
• H2 2026Partnership or licensing agreement with a hospital network or pharmaceutical company50% success
• Q4 2026Publication of preclinical or early clinical data in a peer-reviewed journal40% success